FDA MeetingsThe company remains on track for planned meetings with the FDA on its programs for buntanetap in Parkinson's disease (PD) and Alzheimer's disease (AD).
Patent StrengtheningThe company has filed a new composition of matter patent for a novel crystal form of buntanetap, which offers improved properties such as enhanced solubility and stability, further strengthening its IP portfolio by extending the patent protection by an additional 20 years.
Preclinical DataAnnovis announced positive preclinical data demonstrating combining buntanetap with a GLP-1 agonist (dulaglutide) demonstrated a synergistic effect in a mouse model of Alzheimer's disease (AD).